Aurinia Pharmaceuticals (AUPH) is back in focus after presenting new AURORA 1 Phase 3 data at the EULAR 2026 Congress, highlighting LUPKYNIS outcomes in adults with lupus nephritis.

Aurinia Pharmaceuticals stock has gained momentum recently, with a 30 day share price return of 6.15% and a 90 day share price return of 15.20%. The 1 year total shareholder return of 105.06% and 3 year total shareholder return of 69.49% point to strong longer term interest around the company, partly reinforced by milestones like the new AURORA 1 analysis.

If you are looking beyond Aurinia Pharmaceuticals for other healthcare related ideas, this could be a good moment to review a curated list of 40 healthcare AI stocks.

With Aurinia Pharmaceuticals stock trading at $16.22, an indicated intrinsic discount of about 60% and only a small gap to the $17 analyst target, investors face a key question: is there real upside left, or is the market already pricing in future growth?

Most Popular Narrative: 4.6% Undervalued

At $16.22, Aurinia Pharmaceuticals trades a little below the most followed fair value estimate of $17.00, so the narrative sees only a modest valuation gap.

The company is progressing a potentially best in class pipeline asset, aritinercept, targeting multiple B cell mediated and rare autoimmune diseases, with Phase I success and further clinical studies in multiple indications set to begin this year. It is also leveraging the trend of increased healthcare expenditure and expedited regulatory pathways for rare/orphan disease therapies. (Future revenue growth and pipeline diversification, potential for higher net margins)

Want to understand why a single fair value anchor sits so close to the current Aurinia Pharmaceuticals share price? The narrative leans heavily on specific revenue ramp assumptions, shifting profit margins, and a future earnings multiple that differs from today. The tension between fast top line growth and lower forecast earnings is central. The full story is in how those pieces are expected to fit together.

Based on the most followed narrative, Aurinia Pharmaceuticals is modeled using a $17.00 fair value and a 6.94% discount rate, with detailed assumptions on future revenue growth, profit margins, earnings and share count feeding into that price target. The result is a view that the current share price already reflects much of the expected progress around LUPKYNIS and the pipeline, while leaving a small cushion for upside if execution matches or exceeds those projections.

Result: Fair Value of $17.00 (UNDERVALUED)

However, Aurinia Pharmaceuticals still faces concentration risk around LUPKYNIS, as well as uncertainty over future pricing and reimbursement. Either of these factors could quickly challenge this fair value story.

Next Steps

Given the mix of optimism around Aurinia Pharmaceuticals and the clear risks still in play, it makes sense to look at both sides of the argument and then move quickly to your own view by using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Aurinia Pharmaceuticals?

If you only focus on Aurinia Pharmaceuticals, you could miss other opportunities, so take a few minutes to scan broader stock ideas with the Simply Wall St screener.

• Spot potential bargains early by checking out screener containing 20 high quality undiscovered gems that combine strong fundamentals with lower market attention.
• Strengthen your portfolio’s core using the solid balance sheet and fundamentals stocks screener (48 results) to focus on companies with healthier financial foundations.
• Dial down portfolio stress by reviewing the 67 resilient stocks with low risk scores that highlights businesses with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.